BRIUMVI Dominates

BRIUMVI sales dominated TG Therapeutics’ 2025 performance, with $594 million in U.S. net product sales contributing to total global revenue of $616 million. Net income for the year was $447.2 million, driven by $23 million in Q4 earnings and operating expenses of $328 million. TG projects 2026 operating costs to rise to $350 million, plus an additional $100 million earmarked for subcutaneous BRIUMVI manufacturing and start‑up activities, signalling a focused investment in a key product launch.